FY2021 EPS Estimates for ADMA Biologics Inc (ADMA) Boosted by Oppenheimer

ADMA Biologics Inc (NASDAQ:ADMA) – Analysts at Oppenheimer upped their FY2021 earnings per share (EPS) estimates for shares of ADMA Biologics in a research note issued on Monday, November 12th. Oppenheimer analyst L. Gershell now expects that the biotechnology company will post earnings of $0.25 per share for the year, up from their prior forecast of $0.17. Oppenheimer has a “Buy” rating and a $13.00 price objective on the stock.

ADMA has been the topic of a number of other research reports. BidaskClub raised ADMA Biologics from a “hold” rating to a “buy” rating in a research note on Wednesday, September 5th. Raymond James reaffirmed a “buy” rating and issued a $10.00 target price (down previously from $11.00) on shares of ADMA Biologics in a research note on Friday, October 12th. HC Wainwright initiated coverage on ADMA Biologics in a research note on Tuesday, October 30th. They issued a “buy” rating and a $17.00 target price on the stock. Chardan Capital initiated coverage on ADMA Biologics in a research note on Monday, July 30th. They issued a “buy” rating and a $10.00 target price on the stock. Finally, Maxim Group reaffirmed a “buy” rating and issued a $12.00 target price on shares of ADMA Biologics in a research note on Wednesday, October 17th. Eight equities research analysts have rated the stock with a buy rating, ADMA Biologics has an average rating of “Buy” and a consensus target price of $11.58.

ADMA opened at $5.11 on Wednesday. ADMA Biologics has a 1-year low of $2.42 and a 1-year high of $6.96. The company has a debt-to-equity ratio of 1.11, a quick ratio of 8.88 and a current ratio of 6.32. The company has a market capitalization of $239.16 million, a P/E ratio of -2.68 and a beta of 2.28.

ADMA Biologics (NASDAQ:ADMA) last released its earnings results on Thursday, November 8th. The biotechnology company reported ($0.33) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.31) by ($0.02). ADMA Biologics had a negative return on equity of 155.19% and a negative net margin of 243.42%. The business had revenue of $4.23 million for the quarter, compared to analyst estimates of $5.39 million.

Hedge funds have recently bought and sold shares of the stock. JPMorgan Chase & Co. purchased a new stake in ADMA Biologics in the 1st quarter valued at approximately $182,000. BlackRock Inc. lifted its stake in shares of ADMA Biologics by 59.5% during the 1st quarter. BlackRock Inc. now owns 40,536 shares of the biotechnology company’s stock worth $186,000 after purchasing an additional 15,115 shares during the period. 683 Capital Management LLC lifted its stake in shares of ADMA Biologics by 9.9% during the 2nd quarter. 683 Capital Management LLC now owns 885,000 shares of the biotechnology company’s stock worth $3,991,000 after purchasing an additional 80,000 shares during the period. AMP Capital Investors Ltd purchased a new position in shares of ADMA Biologics during the 2nd quarter worth $109,000. Finally, Renaissance Technologies LLC purchased a new position in shares of ADMA Biologics during the 2nd quarter worth $132,000. 54.99% of the stock is currently owned by hedge funds and other institutional investors.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases. Its lead product candidate is RI-002 derived from human plasma, which has completed Phase III clinical trials for the treatment of primary immune deficiency disease.

Featured Story: What is a capital gain?

Earnings History and Estimates for ADMA Biologics (NASDAQ:ADMA)

Receive News & Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply